Additional information on topics for the Joint Meeting of the TSE
Advisory Committee and Blood Products Advisory Committee may be found in
the following sources:

# A. Plasma derivatives and clearance of spiked TSE infectivity or protease-resistant prion protein

1\. Foster PR. Assessment of the potential of plasma fractionation
processes to remove causative agents of transmissible spongiform
encephalopathy. Transfus Med 1999;9(1):3-14.

2\. Foster PR. Prions and blood products. Ann Med 2000;32(7):501-13.

3\. Foster PR, McLean C, Welch AG, Griffin BD, Hardy JC, Bartley A, et
al. Removal of abnormal prion protein by plasma fractionation. Transfus
Sci 2000;22(1-2):53-6.

4\. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, et
al. Studies on the removal of abnormal prion protein by processes used
in the manufacture of human plasma products. Vox Sang 2000;78(2):86-95.

5\. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, et al.
Monitoring plasma processing steps with a sensitive Western blot assay
for the detection of the prion protein. J Virol Methods
2000;84(1):77-89.

6\. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, et al.
A direct relationship between the partitioning of the pathogenic prion
protein and transmissible spongiform encephalopathy infectivity during
the purification of plasma proteins. Transfusion 2001;41(4):449-55.

# B. Update on vCJD in the UK

1\. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant
Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet
2001;358(9277):208-9.

2\. Cousens S, Smith PG, Ward H, Everington D, Knight RS, Zeidler M, et
al. Geographical distribution of variant Creutzfeldt-Jakob disease in
Great Britain, 1994-2000. Lancet 2001;357(9261):1002-7.

3\. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM.
Epidemiological determinants of the pattern and magnitude of the vCJD
epidemic in Great Britain. Proc R Soc Lond B Biol Sci
1998;265(1413):2443-52.

4\. Ghani AC, Ferguson NM, Donnelly CA, Anderson RM. Predicted vCJD
mortality in Great Britain. Nature 2000;406(6796):583-4.

5\. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Assessment of the
prevalence of vCJD through testing tonsils and appendices for abnormal
prion protein. Proc R Soc Lond B Biol Sci 2000;267(1438):23-9.

6\. Huillard d'Aignaux JN, Cousens SN, Smith PG. Predictability of the
UK variant Creutzfeldt-Jakob disease epidemic. Science
2001;294(5547):1729-31.

7\. Medley GF. Epidemiology. Predicting the unpredictable. Science
2001;294(5547):1663-4.

8\. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic
size and incubation time based on age characteristics of vCJD in the
United Kingdom. Science 2001;294(5547):1726-8.

9\. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert
PJ, et al. Tissue distribution of protease resistant prion protein in
variant Creutzfeldt-Jakob disease using a highly sensitive
immunoblotting assay. Lancet 2001;358(9277):171-80.

**C.** **BSE in the UK**

DEFRA BSE Information, Jan 2002. Public Health.
<http://www.defra.gov.uk/animalh/bse/public-health/public-health-index.html>

# D. Global control of BSE and vCJD

Joint WHO/FAO/OIE Technical Consultation on BSE, Public Health and
Trade. Paris, 11-14 June 2001.
<http://www.who.int/emc/diseases/bse/meeting.htm>

# E. Potential for Bovine Spongiform Encephalopathy in the United States

Cohen JT, Duggar K, Gray GM, Kreindel S, Abdelrahman H, HabteMariam T,
Oryang D, Tameru B. Evaluation of the Potential for Bovine Spongiform
Encephalopathy in the United States. \[The Harvard BSE Risk Assessment\]
Nov 26, 2001. <http://www.aphis.usda.gov/oa/bse/>